Memorial Sloan Kettering surgeon Edmund Bartlett

Edmund Bartlett, MD

Areas of Expertise

My Specialties

  • Soft Tissue Sarcoma
  • Melanoma
  • Merkel Cell Carcinoma

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
English
Share

About Me

What I Do at MSK
  • Assistant Attending Surgeon
Get To Know Me

I am a surgical oncologist who specializes in treating soft tissue sarcoma, melanoma, Merkel cell carcinoma, and splenic neoplasms. I care for patients at MSK Bergen and in Manhattan.

Read more

The treatment of melanoma is changing at a remarkable rate. Recent trials have changed our surgical approach to people with disease that has spread to lymph nodes. The development of effective immunotherapies has revolutionized our ability to treat advanced disease. I work closely with my partners in medical and radiation oncology to determine the best care plan for people with melanoma. I am actively studying ways we can apply the lessons and progress we have made in melanoma to such rare cancers as soft tissue sarcoma and Merkel cell carcinoma. 

For early-stage melanoma, I am interested in using sentinel lymph node biopsy. This special type of biopsy helps us tell how likely it is that the cancer will spread to other parts of the body. I also work to identify people who can avoid the procedure. For higher-risk melanoma, when the disease may have already spread to the lymph nodes, I am working to refine the best types of treatments — including surgery, radiation, and immune therapies — and which order to use them. I am a member of the Melanoma Disease Management Team. This wonderful resource allows care teams to discuss patients in a multidisciplinary approach. We are able to use our collective expertise to identify the best treatment for each individual.

I am also a member of the Sarcoma Disease Management Team. Soft tissue sarcoma is a rare cancer with approximately 80 subtypes. Each subtype behaves and responds to treatment differently. As such, people with soft tissue sarcoma need a care team with deep expertise, one that is dedicated to using a personalized approach for each patient. MSK has been a leader in applying new immune therapy strategies to sarcoma. I am interested in identifying sarcoma subtypes that may be effectively treated by immunotherapy.

I have a particular research interest in the development of clinical trials. My current efforts are focused on using immunotherapy in patients before it has been detected if the cancer will spread. One such trial currently enrolling patients uses immunotherapy treatments in people with sarcoma before surgery in the hopes it will decrease the chance of the cancer coming back. The trials we are developing and the studies we perform are motivated by our interest in providing new treatment options that will maximize chances for a cure and minimize treatment-related complications.

Although the research being done to advance our treatment of people with cancer is critically important, I am first and foremost a surgeon who interested in providing optimal care for my patients. I received dedicated training in the treatment of sarcoma as the Kristen Ann Carr Sarcoma Fellow at MSK and was awarded the Michael E. Burt Award for clinical excellence in 2018.

My Role at MSK

A surgeon is a doctor with special training in many kinds of surgery.

Areas of Expertise

My Specialties

  • Soft Tissue Sarcoma
  • Melanoma
  • Merkel Cell Carcinoma
Education & Honors

Education

  • MD, University of Pennsylvania Medical School

Residencies

  • General Surgery – Hospital of the University of Pennsylvania

Awards and Honors

  • Castle Connolly: America’s Top Doctor (2024)
  • Top Doctors New York Metro Area, Castle Connolly (2023)
  • Castle Connolly: America's Top Doctors (2023)
  • Castle Connolly: New York Magazine Top Doctors (2022)

Fellowships

  • Complex General Surgical Oncology – Memorial Sloan Kettering Cancer Center

Board Certifications

  • Surgery, Complex General Surgical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Bartlett sees patients at two locations.

Office Phone
Location
New York, NY
Montvale, NJ
160 East 53rd Street New York NY 10022
225 Summit Avenue Montvale NJ 07645

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Gastric and Mixed Tumor Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

 

Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts.

Bartlett EK, Grossman D, Swetter SM, Leachman SA, Curiel-Lewandrowski C, Dusza SW, Gershenwald JE, Kirkwood JM, Tin AL, Vickers AJ, Marchetti MA.Ann Surg Oncol. 2022 May 18. doi: 10.1245/s10434-022-11869-7. Online ahead of print.PMID: 35583689

Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases.

Bartlett EK, D’Angelo SP, Kelly CM, Siegelbaum RH, Fisher C, Antonescu CR, Ariyan CE.Front Oncol. 2021 Oct 15;11:725484. doi: 10.3389/fonc.2021.725484. eCollection 2021.PMID: 34722269 

Sentinel Lymph Node Biopsy in Cutaneous Melanoma-Where Do We Stand?

Marchetti MA, Bartlett EK.JAMA Dermatol. 2021 Oct 1;157(10):1159-1160. doi: 10.1001/jamadermatol.2021.3048.PMID: 34406334 

The emerging role of immunotherapy for the treatment of sarcoma.

Klemen ND, Kelly CM, Bartlett EK.J Surg Oncol. 2021 Mar;123(3):730-738. doi: 10.1002/jso.26306. Epub 2020 Dec 1.PMID: 33259653 

Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.

Marchetti MA, Coit DG, Dusza SW, Yu A, McLean L, Hu Y, Nanda JK, Matsoukas K, Mancebo SE, Bartlett EK.JAMA Dermatol. 2020 Sep 1;156(9):953-962. doi: 10.1001/jamadermatol.2020.1731.PMID: 32745161

Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Bartlett EK, Peters MG, Blair A, Etherington MS, Elder DE, Xu XG, Guerry D, Ming ME, Fraker DL, Czerniecki BJ, Gimotty PA, Karakousis GC. Ann Surg Oncol. 2016 Jan;23(1):250-6.

Current staging and prognostic factors in melanoma. Bartlett EK, Karakousis GC. Surg Oncol Clin N Am. 2015 Apr;24(2):215-27.

Outcomes after resection of leiomyosarcomas of the inferior vena cava: a pooled data analysis of 377 cases. Wachtel H, Gupta M, Bartlett EK, Jackson BM, Kelz RR, Karakousis GC, Fraker DL, Roses RE. Surg Oncol. 2015 Mar;24(1):21-7.

The rise in metastasectomy across cancer types over the past decade. Bartlett EK, Simmons KD, Wachtel H, Roses RE, Fraker DL, Kelz RR, Karakousis GC. Cancer. 2015 Mar 1;121(5):747-57.

Preoperative radiation for retroperitoneal sarcoma is not associated with increased early postoperative morbidity. Bartlett EK, Roses RE, Meise C, Fraker DL, Kelz RR, Karakousis GC. J Surg Oncol. 2014 May;109(6):606-11

Publications on PubMed

Visit PubMed for a full listing of Dr. Bartlett’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Edmund Bartlett discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures